Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3619-3625

  Thill, Marc ^a   Fischer, Dorothea ^a   Becker, Steffi ^a   Cordes, Tim ^a   Dittmer, Christine ^a   Diedrich, Klaus ^a   Salehin, Darius ^b   Friedrich, Michael ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Helios Hospital Krefeld   (Germany)

Author keywords

15 hydroxyprostaglandin dehydrogenase; Breast cancer; Cyclooxygenase 2; Prostaglandin metabolism; Vitamin D receptor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALCITRIOL; CYCLOOXYGENASE 2; PROSTAGLANDIN; VITAMIN D; VITAMIN D RECEPTOR;

BENIGN TUMOR; BREAST CANCER; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VITAMIN D METABOLISM; WESTERN BLOTTING;

BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; PROSTAGLANDINS; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 68549132402     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (68)

1. Xie WL, Robertson DL and Simmons DL: Mitogen-inducible prostaglandin G/H synthase: a target for nonsteroidal antiiflammatory drugs. Drug Dev Res 25: 249-265, 1991.
2. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxid synthase-2. Cell 83: 493-501, 1995.
3. Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270(3 Pt 1): G393-400, 1996.
4. O'Neill GP and Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330(2): 156-160, 1993. (Pubitemid 23265121)
5. Denken C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 97(12): 2978-2987, 2003. (Pubitemid 36676251)
6. Herschmann HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 13: 241-256, 1994.
7. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55(12): 2556-2559, 1995.
8. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verbürg KM, Yu SS, Zhao WW and Geis GS: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282(20): 1921-1928, 1999.
9. Choe MS, Zhang X, Shin HJ, Shin DM and Chen ZG: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4(9): 1448-1455, 2005.
10. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrebach S and Dubois RN: Up-regulation of cyclooxygenase gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994. (Pubitemid 24294584)
11. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y and Frazier ML: Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117: 350-358, 1999. (Pubitemid 29352943)
12. Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA and Derchain SFM: Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer 17: 607-614, 2007. (Pubitemid 46744003)
13. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM and Feldman D: Calcitriol and enistein actions to inhibit the prostaglandin pathway: potemtial combinationtherapy to treat prostate cancer. J Nutr 137: 205S-210S, 2007. (Pubitemid 46052882)
14. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B and Dubinett SM: Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 7(1): 30-39, 2005.
15. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003. (Pubitemid 36135884)
16. Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997. (Pubitemid 27152551)
17. Zimmermann KC, Sarbia M, Weber A, Bochard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204, 1999. (Pubitemid 29062978)
18. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506, 2001. (Pubitemid 32701408)
19. Basu GD, Liang WS, Tephan DA, Wegener LT, Conley CR, Pockaj BA and Mukherje P: A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 8(6): R69, 2006.
20. Hussain T, Gupta S and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191: 125-135, 2003.
21. Basler JW and Piazza GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171: S59-62, discussion S62-63, 2004.
22. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO and Scambia G: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13(8): 1205-1211, 2002. (Pubitemid 34960128)
23. Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998. (Pubitemid 28257578)
24. Lim SC, Park SY and Do NY: Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep 10(5): 1073-1079, 2003.
25. Chu J, Lloyd FL, Trifan OC, Knapp B and Rizzo MT: Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2(1): 1-7, 2003.
26. Brueggemeier RW and Diaz-Cruz ES: Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Minerva Endocrinol 31(1): 13-26, 2006.
27. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG and Mokbel K: Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol 96(5): 424-428, 2007. (Pubitemid 47519449)
28. 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 82: 2000-2006, 2000. (Pubitemid 30326462)
29. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12(12): 1063-1073, 1998.
30. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26: 65-72, 2005. (Pubitemid 40207700)
31. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP: 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66(15): 7818-7823, 2006. (Pubitemid 44289243)
32. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K and Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004. (Pubitemid 39657428)
33. Liu S, Stromberg A, Tai HH and Moscow JA: Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. Mol Cancer Res 2(8): 477-487, 2004. (Pubitemid 39121510)
34. Anggard E: The biological activities of three metabolites of prostaglandin E1. Acta Physiol Scand 66: 509-510, 1966.
35. Tai HH, Ensor CM, Tong M, Zhou H and Yan F: Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 68-69: 483-493, 2002.
36. Ensor C and Tai HH: 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal 12: 313-319, 1995.
37. +-dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 141: 581-597, 2000. (Pubitemid 32250482)
38. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
39. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S and DuBois RN: 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217-3223, 2005. (Pubitemid 40223783)
40. Gee JR, Montoya RG, Khaled HM, Sabichi AL and Grossman HB: Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 21: 266-270, 2003.
41. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK and Gorham ED: Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2: 1176-1178, 1989. (Pubitemid 19275448)
42. Hanchette CL and Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861-2869, 1992.
43. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80: 1678S-1688, 2004.
44. Palmer HG, Gonzalez-Sancho J M, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M. Cano A, de Herreros AG, Lafarga M and Munoz A: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154: 369-387, 2001. (Pubitemid 34286147)
45. 3 receptor knockout mice. Mol Cell Endocrinol 200: 67-80, 2003. (Pubitemid 36331916)
46. Krishnan AV, Peehl DM and Feldman D: Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 88: 363-371, 2003. (Pubitemid 36119910)
47. Chen TC and Holick MF: Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14(9): 423-430, 2003.
48. Peehl DM, Krishnan AV and Feldman D: Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133(7 Suppl): 2461S-2469S, 2003.
49. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM and Feldman D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65(17): 7917-7925, 2005. (Pubitemid 41297270)
50. Miller GJ: Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev 17: 353-360, 1998.
51. Zhuang SH and Burnstein KL: Antiproliferative effect of 1α25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent Gl accumulation. Endocrinology 139: 1197-1207, 1998.
52. Konety BR and Getzenberg RH: Vitamin D and prostate cancer. Urol Clin North Am 29: 95-106, 2002.
53. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K and Narvaez CJ: Vitamin D3 receptor as a target for breast cancer prevention. J Nutr 133: 2425-2433S, 2003. (Pubitemid 36828849)
54. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9): e45, 2001.
55. Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N and Colston KW: Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 85: 171-175, 2001. (Pubitemid 32695735)
56. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002. (Pubitemid 34408488)
57. Boyle BJ, Zhao XY, Cohen P and Feldman D: Insulin-like growth factor-binding protein-3 mediates 1,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165: 1319-1324, 2001. (Pubitemid 32210283)
58. Krishnan AV, Peehl DM and Feldman D: The role of vitamin D in prostate cancer. Recent Results Cancer Res 164: 205-221, 2003.
59. Krishnan AV, Peehl DM and Feldman D. Vitamin D and prostate cancer. In: Vitamin D, Feldman D, Pike JW and Glorieux F (eds.). 2nd ed. San Diego: Academic Press, pp. 1679-1707, 2005.
60. Kemmis CM, Salvador SM, Smith KM and Welsh J: Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136(4): 887-892, 2006.
61. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ and Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11(9): 3579-3586, 2005. (Pubitemid 40627915)
62. Srinath P, Rao PN, Knaus EE and Suresh MR: Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res 23: 3923-3928, 2003. (Pubitemid 37474344)
63. Narayanan BA, Narayanan NK, Pittman B and Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10: 7727-7737, 2004. (Pubitemid 39557538)
64. Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M, Abbattista A and Lobelle JP: Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 26(8): 1253-1259, 2008.
65. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J and Henner WD; ASCENT (AIPC Study of Calcitriol Enhancing Taxotere) Investigators: Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112(2): 326-330, 2008.
66. Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I and Gordon M: Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 31(2): 157-162, 2008.
67. Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH and Hanna N: Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 3(4): 374-379, 2008.
68. Xiao H, Zhang Q, Lin Y, Reddy BS and Yang CS: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122(9): 2115-2124, 2008.